Lapatinib [lapatinib]
topical
37
- Terms
-
lapatinib ditosylát
Tyverb
-
GW 282974X
GW 572016
GW-282974X
GW-572016
GW282974X
GW572016
Lapatinib Ditosylate
N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
Tykerb
Persistent link
https://www.medvik.cz/link/D000077341
Definition
A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.
- DUI
- D000077341 MeSH Browser
- CUI
- M0473129
- History note
- 2019 (2004)
- Public note
- 2019; LAPATINIB was indexed under QUINAZOLINES 2004-2018
Allowable subheadings
- AD
- administration & dosage 2
- AE
- adverse effects
- AG
- agonists
- AA
- analogs & derivatives
- AN
- analysis
- AI
- antagonists & inhibitors
- BL
- blood
- CF
- cerebrospinal fluid
- CS
- chemical synthesis
- CH
- chemistry
- CL
- classification
- EC
- economics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics
- PD
- pharmacology
- PO
- poisoning
- RE
- radiation effects
- ST
- standards
- SD
- supply & distribution
- TU
- therapeutic use 6
- TO
- toxicity
- UR
- urine
...
Occurrences in Medvik records